Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis

Concerns have arisen regarding the risk of ischemic heart disease with the novel antiangiogenic agent bevacizumab, a recombinant humanised monoclonal antibody to the vascular endothelial growth factor that is widely used in cancer treatment. Currently, the role of bevacizumab in ischemic heart disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xing-Lin, Lei, Ying-Hong, Liu, Cun-Fei, Yang, Qun-Fang, Zuo, Pei-Yuan, Liu, Cheng-Yun, Chen, Chang-Zhong, Liu, Yu-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688569/
https://www.ncbi.nlm.nih.gov/pubmed/23818962
http://dx.doi.org/10.1371/journal.pone.0066721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688569/
https://www.ncbi.nlm.nih.gov/pubmed/23818962
http://dx.doi.org/10.1371/journal.pone.0066721

Ejemplares similares